Get the Stockscreener App
1.805
7.44%
0.125
Alx Oncology Holdings Inc stock is traded at $1.805, with a volume of 300.37K.
It is up +7.44% in the last 24 hours and up +56.96% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.68
Open:
$1.7
24h Volume:
300.37K
Relative Volume:
1.07
Market Cap:
$98.06M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.6077
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
+20.33%
1M Performance:
+56.96%
6M Performance:
+248.39%
1Y Performance:
+36.74%
1-Day Range:
$1.66
$1.879
1-Week Range:
$1.36
$1.93
52-Week Range:
$0.404
$2.27
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.8087 | 91.09M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.42 | 119.76B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.00 | 79.35B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
846.09 | 51.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.32 | 44.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
342.47 | 38.18B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Jefferies | Buy |
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
Wilson Sonsini Advises ALX Oncology on Public Offering - Wilson Sonsini
CD47 Protein May Predict Evorpacept Success in Metastatic Breast Cancer - Cure Today
ALX Oncology Prices $150 Mln Offering Of Shares And Pre-funded Warrants - Nasdaq
ALX Oncology announces pricing of underwritten offering; shares up nearly 15% - MSN
ALX Oncology prices $150 million stock offering at $1.57 per share - Investing.com Nigeria
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera in Advanced HER2-Positive Breast Cancer - Investing News Network
ALX Oncology reports CD47 biomarker findings in breast cancer trial By Investing.com - Investing.com Nigeria
ALXO Unveils Promising Data from Evorpacept Trial in Breast Canc - GuruFocus
ALX Oncology announces major underwritten public equity offering - TipRanks
ALX Oncology Announces Pricing of Underwritten Offering - The Manila Times
Biotech ALX Oncology raises $150M to fund cancer drug trials - Stock Titan
ALX Oncology reports CD47 biomarker findings in breast cancer trial - Investing.com
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - The Manila Times
ALX Oncology Holdings Inc Announces New Clinical Trial Data - TradingView
What is ALX Oncology Holdings Inc.’s book value per shareTrade Exit Report & Daily Chart Pattern Signals - Mfd.ru
Can ALX Oncology Holdings Inc. reach all time highs this yearDip Buying & Daily Volume Surge Trade Alerts - Mfd.ru
IPO Launch: Is ALX Oncology Holdings Inc affected by consumer sentimentPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn
VIX Spike: Is ALX Oncology Holdings Inc in accumulation or distribution phase2025 Technical Patterns & Verified Swing Trading Watchlist - baoquankhu1.vn
Investment Report: Will ALX Oncology Holdings Inc stock hit new highs in YEARIPO Watch & AI Forecasted Entry/Exit Points - baoquankhu1.vn
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ALX Oncology increases shares reserved for inducement equity plan By Investing.com - Investing.com Nigeria
ALX Oncology increases shares reserved for inducement equity plan - Investing.com
ALX Oncology Expands Inducement Equity Plan for Hiring - TipRanks
Aug Volume: How does QuantumScape Corporation correlate with NasdaqEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
Downgrade Watch: Is Teledyne Technologies Incorporated a cyclical or defensive stockMarket Rally & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Highs Report: Does ALX Oncology Holdings Inc. have high return on assetsJuly 2025 Market Mood & AI Powered Buy and Sell Recommendations - bollywoodhelpline.com
Fed Watch: Will Hennessy Advisors Inc stock hit new highs in YEARLong Setup & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference - MarketBeat
ALX Oncology : Investor Presentation ALX presentation at JPM 2026 12Jan2026 FINAL (698186) - marketscreener.com
Aug Spikes: Will ALX Oncology Holdings Inc stock recover after earnings - baoquankhu1.vn
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks - Yahoo Finance
Stock Report: Why ALX Oncology Holdings Inc stock remains undervaluedPortfolio Performance Summary & AI Enhanced Trading Alerts - Bộ Nội Vụ
Is ALX Oncology Holdings Inc. stock trading near support levelsJuly 2025 Fed Impact & Weekly Top Performers Watchlists - Улправда
Hedge Fund Moves: How geopolitical tensions affect ALX Oncology Holdings Inc. stockJuly 2025 Update & Consistent Profit Trading Strategies - Улправда
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Why ALX Oncology Holdings Inc. stock remains undervaluedWeekly Market Report & Daily Momentum Trading Reports - Улправда
How ALX Oncology Holdings Inc. stock compares to market leadersJuly 2025 Momentum & Safe Capital Growth Stock Tips - Улправда
How geopolitical tensions affect ALX Oncology Holdings Inc. stock2025 Macro Impact & Verified Trade Idea Suggestions - Улправда
ALX Oncology Advances Separate Clinical Trials Evaluating - GlobeNewswire
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Meme Stocks: Will ALX Oncology Holdings Inc stock deliver consistent dividends2025 Valuation Update & Weekly Market Pulse Updates - moha.gov.vn
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 32.0% - Defense World
ALXOAmended Statement of Beneficial Ownership (3/a) - ADVFN
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights - ADVFN
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update - ADVFN
ALX Oncology (NASDAQ:ALXO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Aug PostEarnings: What technical charts say about ALX Oncology Holdings Inc. stock2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - DonanımHaber
What momentum indicators show for ALX Oncology Holdings Inc. stockMarket Risk Summary & AI Driven Price Forecasts - Улправда
Alx Oncology: A Study in Contrasting Market Sentiment - AD HOC NEWS
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alx Oncology Holdings Inc Stock (ALXO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
1.51%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):